Online Only Articles

Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia

Center of Internal Medicine, Goethe University, Frankfurt, Germany
Amgen Research (Munich) GmbH, Germany
Amgen Research (Munich) GmbH, Germany
Amgen Research (Munich) GmbH, Germany
Medical Department A, University of Münster, Germany
Department for Internal Medicine III, University Ulm, Germany
Medical Department II, Christian-Albrechts University, Kiel, Germany
Medical Department II, Christian-Albrechts University, Kiel, Germany
Medical Department II, Christian-Albrechts University, Kiel, Germany
Department of Haematology, Cardiff University, Cardiff, UK
Department for Hematology and Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
Metronomia Clinical Research GmbH, München, Germany
Department of Internal Medicine II, Universitätsklinikum, Würzburg, Germany
Comprehensive Cancer Center Mainfranken, Universitätsklinikum Würzburg, Germany
Vol. 102 No. 4 (2017): April, 2017 https://doi.org/10.3324/haematol.2016.153957